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Background: Adverse drug event (ADEs) are a significant cause of emergency
department (ED) visits and consequent hospitalization. Preventing ADEs and their
related ED visits in outpatients remains a public health safety challenge. In this context,
the aims of the present study were to describe the frequency, seriousness and
preventability of outpatients’ ADE-related ED visits and hospitalizations in the Italian
general population, and to identify the presence of potential predictors of ADE-related
hospitalization.
Methods: We performed a nationwide, multicentre, observational, retrospective study
based on reports of suspected ADEs collected between January 1, 2007 and December
31, 2018 in 94 EDs involved in the MEREAFaPS project. Patients’ demographic
characteristics, their clinical status, suspected and concomitant drugs, ADE
description, and its degree of seriousness, were collected. Causality and preventability
were assessed using validated algorithms, and logistic regression analyses were used to
estimate the reporting odds ratios (RORs) with 95% confidence intervals (CIs) of ADE-
related hospitalization, considering the following covariates: age, sex, ethnicity, number of
implicated medications, parenteral administration, presence of interaction, therapeutic
error, and/or complementary and alternative medicines (CAM).
Results: Within 12 years, 61,855 reports of suspected ADE were collected, of which
18,918 (30.6%) resulted in hospitalization (ADE defined as serious). Patients were mostly
female (56.6%) and Caucasians (87.7%), with a mean age of 57.5 ± 25.0 years. 58% of
patients were treated with more than two drugs, and 47% of ADEs leading toin.org April 2020 | Volume 11 | Article 4121
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Frontiers in Pharmacology | www.frontiershospitalization were preventable. Anticoagulants, antibiotics, and nonsteroidal anti-
inflammatory drugs (NSAIDs) were the most frequently implicated agents for ED visits
and/or hospitalization, which included clinically significant ADEs, such as haemorrhage for
anticoagulants, moderate to severe allergic reactions for antibiotics, and dermatologic
reactions and gastrointestinal disturbances for NSAIDs. Older age (1.54 [1.48–1.60]),
higher number of concomitantly taken drugs (2.22 [2.14–2.31]), the presence of drug-
drug interactions (1.52 [1.28–1.81]), and therapeutic error (1.54 [1.34–1.78]), were
significantly associated with an increased risk of hospitalization.
Conclusion: Our long-term active pharmacovigilance study in ED provided a valid
estimation of ADE-related hospitalization in a representative sample of the Italian
general population and can suggest further focus on medication safety in outpatients,
in order to early recognise and prevent ADEs.Keywords: emergency department, hospitalization, adverse drug events, pharmacovigilance, drug safety,
preventability, seriousnessINTRODUCTION
Adverse drug events (ADEs) are the most common cause of
iatrogenic harm in health care and have received attention in
national patient safety initiatives (Shehab et al., 2016). Moreover,
ADEs are a significant cause of emergency department (ED)
visits and hospitalizations (Budnitz et al., 2011).
In outpatients, in which 90% of prescription drug
expenditures occur (Shehab et al., 2016), an early identification
and prevention of ADEs remain a public health and patient
safety challenge worldwide, with efforts often focused on
medication abuse/misuse, medication errors, and reducing
potentially inappropriate prescribing for general population,
particularly in children (Carnovale et al., 2014; Lombardi et al.,
2018) and elderly, as defined by the Beers criteria (By the
American Geriatrics Society Beers Criteria Update Expert,
2015). Patients in primary care and some post-acute care
settings can have complex medication regimens, at times
prescribed by multiple clinicians, with far less monitoring
compared with hospitalized patients.
EDs are an essential part of health care systems, serving as an
interface between hospitals and communities, and could
constitute the most important source of information about the
clinical and economic characteristics of ADEs (Zed et al., 2013;
Carnovale et al., 2014).
Several studies have been published on ADEs as a cause of ED
admissions, but none of those available in the literature has been
conducted at national level and for a long observational period
(Perrone et al., 2014; Lombardi et al., 2018; Lombardi et al.,
2019). Furthermore, few studies evaluated the presence of
specific variables among population and/or medication
characteristics which can contribute to an ADE as a cause
of hospitalization.
In this context, assuming the presence of predictors of
hospitalization related to ADEs in the general population, we
first performed this study to describe the frequency,
preventability and seriousness of ADEs in Italy and,in.org 2subsequently, for estimate the risk of hospitalization associated
to ADEs, by means of a 12-year active pharmacovigilance
surveillance in EDs. For the first time the characteristics of the
MEREAFaPS Study database have been described.MATERIAL AND METHODS
This is an observational retrospective study performed on data
retrieved by pharmacovigilance reports of suspected ADE
collected between January 1, 2007 and December 31, 2018 in
the EDs participating to the MEREAFaPS Study (“Monitoraggio
Epidemiologico delle Reazioni e degli Eventi Avversi da Farmaci in
Pronto Soccorso” - “Epidemiological Monitoring of Adverse Drug
Reactions and Events leading to Emergency Department”), an on-
going multicentre study of active pharmacovigilance (Lombardi
et al., 2018; Lombardi et al., 2019). This is the first nationwide
pharmacovigilance study performed in Italy with an “active”
approach and based on electronic EDmedical records containing
detailed information on patient populations, thereby allowing
consideration of modifying factors such as polypharmacy and
comorbidity, as well as sociodemographic characteristics.
The study involves a total of 94 EDs belonging to general
hospitals serving different areas of Italy. These hospitals are
equally distributed through the national territory, in five Italian
Regions: Lombardy and Piedmont (north), Tuscany and Emilia-
Romagna (centre), and Campania (south). The EDs involved in
the present study allow to reach an estimated coverage of over
45% of the Italian population (more than 28millions of
inhabitants) (Italian Statistics Bureau (ISTAT), 2018).
All ADEs leading to ED visit were collected from the ED
clinical charts and hospitalization data were collected from the
hospitals discharge database. ED trained monitors (i) evaluated
all ED visits, consulting ED clinical charts and hospital discharge
database, (ii) identified those related to ADEs and, following the
Italian pharmacovigilance legislation (Mazzitello et al., 2013),
(iii) filled out the specific report form. ED trained monitorsApril 2020 | Volume 11 | Article 412
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both electronic and paper-based medical records. An ad hoc
MEREAFaPS database was constructed, retrieving the following
information: (1) patients’ demographic characteristics (age,
gender, ethnic group); (2) patients’ clinical status on ED
admission; (3) suspected medications (for each one,
administration route, therapy duration, dosages, and
therapeut ic indicat ion were recorded) ; (4) use of
complementary and alternative medicines (CAM); (5) ADEs
description; (6) ADEs outcome (resolution with sequelae, still
unresolved, complete resolution, improvement, death, and
not available).
Suspected and concomitant medications were classified
according to the Anatomical Therapeutic Chemical (ATC)
classification system. ADEs reported from outpatients having
at least one clinical manifestation related to any medication were
included in the analysis, considering all ATC classes. Patients
who developed an ADE while in the ED were excluded. ADEs
description according to diagnosis and symptoms was coded
using the Medical Dictionary for Regulatory Activities
(MedDRA) and organized by System Organ Class (SOC) and
Preferred Term (PT) (Lombardi et al., 2018; Lombardi
et al., 2019).
A multidisciplinary team composed by experts in clinical
pharmacology (NL, GC, AC, AM, GDV), toxicology (AV, MV),
and pharmcoepidemiology (AB, MT, RB), performed a clinical
evaluation of cases included in the analysis, in order to assess the
causality relationship between the suspected medications and
their related ADEs (Naranjo et al., 1981). In particular, the
sections of the Naranjo scale concerning to dechallenge and/or
rechallenge were taken into consideration. In pharmacovigilance,
“dechallenge” refers to the stopping of the suspected drug,
usually after an ADE or at the end of a planned treatment.
Dechallenges may be complete or partial. That is, the drug is fully
stopped or decreased in dose and the ADEmay fully disappear or
only partially decrease. A positive dechallenge refers to the ADE
disappearing after the stopping of the drug. On the contrary, a
negative dechallenge refers to the ADE not disappearing after the
stopping of the drug. Moreover, “rechallenge” refers to the
restarting of the same suspected drug after having stopped it,
usually for an ADE. Rechallenges may also be complete or
partial. A positive rechallenge refers to the ADE recurring after
restarting the drug. To have this occur, the ADE had to have
previously disappeared after the dechallenge in order for it to
restart. A negative rechallenge is the case where the ADE does
not recur after the drug is restarted. It is important to consider
that the applicability of these two concepts can be affected by
certain limitation (Mittal and Gupta, 2015). In particular,
dechallenge may not be applicable where the suspected drug is
a one-dose treatment (i.e., vaccine), ADE resulting in death or
occurring after discontinuation of drug. Moreover, the
evaluation can be difficult to apply, such as in irreversible or
long-lasting reaction. Finally, dechallenge cannot be addressed in
cases of ADEs showing spontaneous recovery despite
continuation of therapy. Considering rechallenge, it may range
from a similar episode in the patient’s anamnesis to a trueFrontiers in Pharmacology | www.frontiersin.org 3planned prospective re-exposure. Because of ethical and
clinical concerns, a true rechallenge is a generally very rare
evenience, particularly in serious ADEs. All of these limitations
will be considered when applying the Naranjo scale.
Preventability of ADEs (categorized as definitely or probably
preventable, or not preventable) was assessed using the
Schumock and Thornton algorithm (Schumock and Thornton,
1992). Considering the specific section of the pharmacovigilance
report form (available from June 2012) and according to Good
Pharmacovigilance Practices (GVP) - Module VI (Rev 2),
monitors retrieved information concerning the cause of ADEs,
and recorded, only when reported, whether ADEs were due to
misuse/abuse/medication error/overdose or drug-drug
interactions (European Medicine Agency (EMA), 2017).
Descriptive statistics were used to summarize data.
Categorical data were reported as frequencies and percentages
and compared using the Chi-square test, whereas continuous
data were reported as median values with the related
interquartile ranges (IQRs) and compared using the Mann-
Whitney test. Logistic regression analyses were used to
estimate the reporting odds ratios (RORs) with 95% confidence
intervals (CIs) of ADE-related hospitalization, considering the
following covariates: age, sex, ethnicity, number of implicated
medications, parenteral administration, presence of interaction,
therapeutic error, and/or complementary and alternative
medicines (CAM).
Adjustment was performed for all the above mentioned
covariates. All results were considered to be statistically
significant at p < 0.05. Data management and statistical
analysis were carried out using STATA 14.
The coordinating centre of Tuscany Region (Italy) approved
MEREAFaPS Study (Notification number 1225 - December 21,
2009), and the local institutional ethics committee approved
MEREAFaPS Study (Study number 3055/2010, Protocol number
45288 - August 6, 2014) according to the legal requirements
concerning observational studies. Due to the retrospective nature
of the present study and data anonymization, patient’s consent to
participate was not required.RESULTS
During the 12-year study period, a total of 61,855 ADE reports
related to ED visits was evaluated; of them, 18,918 (30.6%)
resulted in hospitalization. We estimated a rate of ADE-related
visits and hospitalization of 5,154.6 and 1,576.5 reports per year,
respectively. Considering that during the study period our
monitors evaluated around 45millions of ED clinical charts, we
estimated an overall incidence rate of 1.4 per 1,000 ADE-related
ED visits and 0.4 per 1,000 ADE-related hospitalizations. Table 1
and Supplementary Table 1 report demographic and clinical
characteristics of cases. Out of 61,855 ADE reports, 30,343
(49.0%) were defined as serious, and 160 (0.3%) of them were
fatal. Most of ADEs occurred in females (n=35,010; 56.6%) and
in Caucasians (n=54,232; 87.7%), with a mean ( ± standard
error) patients’ age of 57.5 ± 25.0 years. A total of 31,460 (50.9%)April 2020 | Volume 11 | Article 412
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resolution. For 8408 (13.6%) ADEs data on the outcome were
not available. Overall, at time of ADE occurrence, patients were
treated with more than 2 suspected drugs (n=35,853; 58.0%), and
49.2% of patients exposed to polypharmacy (≥5 concomitant
drugs) were hospitalized. Visits were related to vaccines in 13.2%
of cases; while CAMs were reported in 1.2% of reports. 1,574
(2.5%) cases of ADE were associated to drug abuse/misuse, andFrontiers in Pharmacology | www.frontiersin.org 41,436 (2.3%) were judged as preventable. Of them, 47% led to
hospitalization. Dechallenge and rechallenge were positive in
49.6% and 0.8% of cases, respectively (data not shown). Among
visits and hospitalizations, a statistically significant difference
was observed for age groups (p=0.001), ethnicity (p < 0.001),
number of suspected drugs (p < 0.001), type of medication (p <
0.001), presence of a suspected drug with parenteral
administration (p < 0.001), type of event (p < 0.001), and
preventability (p < 0.001).
Table 2 reports the suspected drug classes. Out of 78,361
suspected agents, 16,348 belonged to the ATC class B (Blood and
blood forming organs), 15,920 to the ATC class N (Nervous
system), 14,664 to the ATC class J (Antinfectives for systemic
use), 8,861 to the ATC class C (Cardiovascular system), 8,150 to
the ATC class A (Alimentary tract and metabolism), 7,717 to the
ATC class M (Musculoskeletal system), 1,722 to the ATC class L
(Antineoplastic and immunomodulating agents), 1,459 to the
ATC class R (Respiratory system), 1,146 to the ATC class H
(Hormonal preparations), and 970 to the ATC class G
(Genitourinary system and sex hormones).
Table 3 reports the most commonly reported suspected drugs
leading to hospitalization by patient age. Overall, warfarin was
the most reported one, followed by acetylsalicylic acid,
amoxicillin-clavulanate, short-acting insulin, and lorazepam.
Among patients aged ≤19 years, amoxicillin-clavulanate was
the most reported drug, followed by paracetamol, ibuprofen,
ketoprofen, and hexavalent vaccine. In elderly, hospitalization
was mainly related to warfarin, acetylsalicylic acid, short-acting
insulin, metformin, and furosemide use.
Table 4 reports adverse event manifestation by most
commonly reported suspected drug classes. Anticoagulants and
antiplatelet agents (n=16,054), antibacterials (n=12,389),
nonsteroidal anti-inflammatory drugs (NSAIDs) (n=6,617),
insulins and oral diabetes agents (n=6,042), opioid and non-
opioid analgesics (n=5,321), and sedative or hypnotic agents
(n=3,802) were the most commonly suspected agents for ED
visits and hospitalization. Haemorrhagic events were frequently
associated to anticoagulants and antiplatelet agents (50.5% of
visits), moderate to severe dermatologic reactions and
gastrointestinal disturbances to antibacterials (42.7% and
10.1%, respectively) and to NSAIDs (27.9% and 14.4%,
respectively), hypoglycaemic events to antidiabetic agents
(59.4%), and neurologic events to analgesics (22.7%) and to
sedative or hypnotic agents (33.0%).
Multivariate logistic regression analysis showed that, after
adjustment for potential confounding, the risk of hospitalization
was significantly higher for older age (ROR 1.54 [95% CI, 1.48–
1.60]), higher number of concomitantly suspected drugs (ROR
2.22 [95% CI, 2.14–2.31]), presence of drug-drug interactions
(ROR 1.52 [95% CI,1.28–1.81]), and therapeutic error (ROR 1.54
[95% CI, 1.34–1.78]) (Figure 1).DISCUSSION
This study aimed to describe the frequency and the clinical
characteristics of ADEs leading to ED visit and hospitalization inTABLE 1 | Case characteristics.









≤5 3,211 (5.2) 371 (11.6) <0.0001
6–19 2,801 (4.5) 509 (18.2)
20–64 26,039 (42.1) 6,469 (24.8)
65–79 16,066 (26.0) 5,479 (34.1)
≥80 13,175 (21.3) 5,817 (44.2)
Not available 563 (0.9) 273 (48.5)




Female 35,010 (56.6) 10,592 (30.3) 0.042
Male 26,845 (43.4) 8,326 (31.0)
Patient ethnicity
Asian 892 (1.4) 186 (20.9) <0.0001
Black or African
American
550 (0.9) 154 (28.0)
Caucasian 54,232 (87.7) 16,743 (30.9)
Other 156 (0.3) 38 (24.4)
Not available 6,025 (9.7) 1,797 (29.8)
No. of suspected drugs
involved in the ADE
1 26,002 (42.0) 4,974 (19.1) <0.0001
2 10,512 (17.0) 2,765 (26.3)
3–4 10,397 (16.8) 3,828 (36.8)
≥5 14,944 (24.2) 7,351 (49.2)
Type of medication
Drug 60,684 (98.1) 18,793 (31.0) <0.0001





No 53,665 (86.8) 16,270 (30.3) <0.0001
Yes 8,190 (13.2) 2,648 (32.3)
Presence of CAM
Yes 728 (1.2) 231 (31.7) 0.500
No 61,127 (98.8) 18,687 (30.6)
Type of event
Abuse/misuse 1,574 (2.5) 905 (57.5) <0.0001
Interactions 539 (0.9) 271 (50.3)
Overdose 387 (0.6) 166 (42.9)
Therapeutic errors 832 (1.4) 352 (42.3)
Preventability
Yes 1,436 (2.3) 675 (47.0) <0.0001
No 12,535 (20.3) 2,831 (22.6)
Non assessable 5,207 (8.4) 1,695 (32.6)
Not applicable 42,677 (69.0) 13,717 (32.1)
Total 61,855 (100) 18,918 (30.6)April 2020 | Volume 11 | Article 412
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Drug class ED visits for
ADEs






No. of suspected agents
26,335 (row %)
Blood and blood forming
organs
16,348 6,156
Anticoagulants 10,252 (13.1) 3,899 (38.0)
Vitamin K antagonists
(warfarin)
8,045 (10.3) 2,924 (36.3)
Factor Xa inhibitors 1,017 (1.3) 458 (45.0)
Unfractionated and Low-
molecular-weight heparins
744 (0.9) 303 (40.7)
Direct thrombin inhibitors 446 (0.6) 214 (48.0)
Antiplatelets 5,802 (7.4) 2,180 (37.6)
Acetylsalicylic acid 4,153 (5.3) 1,523 (36.7)
Platelet P2Y12 receptor
antagonists
1,508 (1.9) 603 (40.0)
Enzymes (alteplase) 141 (0.2) 54 (38.3)
Antihemorrhagic, antianemic
and perfusion preparations
294 (1.1) 77 (26.2)
Nervous system 15,920 6,426
Analgesics 5,474 (7.0) 1,400 (25.6)
Opioid analgesics (codeine
combinations)
2,988 (3.8) 783 (26.2)
Non-opioid analgesics
(paracetamol)
2,333 (3.0) 586 (25.1)
Antimigraine preparations 153 (0.2) 31 (20.3)
Sedative or hypnotic agents 3,802 (4.8) 2,028 (53.3)
Benzodiazepines 2,659 (3.4) 1,437 (54.0)
Nonbenzodiazepine or
nonbarbiturate sedatives
1,143 (1.5) 591 (51.7)
Antidepressants 2,140 (2.7) 971 (45.4)
Antipsychotics 1,967 (2.5) 933 (47.4)
Antiepileptics 1,814 (2.3) 862 (47.5)




Antibacterials 12,389 (15.8) 2,350 (19.0)
Penicillins (amoxicillin-
clavulanate)
7,057 (9.0) 1,190 (16.9)
Quinolones (levofloxacin) 1,975 (2.5) 485 (24.5)
Cephalosporins (ceftriaxone) 1,354 (1.7) 307 (22.7)
Macrolides (clarithromycin) 1,310 (1.7) 218 (16.6)
Sulfamethoxazole and
trimethoprim
353 (0.4) 82 (23.2)
Other antibacterials 340 (0.4) 68 (20.0)
Vaccines 1,720 (2.2) 184 (10.7)
Antivirals and antiretrovirals 330 (0.4) 66 (20.0)
Other antinfectives agents 225 (0.3) 60 (26.7)
Cardiovascular system 8,861 3,623
Renin-angiotensin system
inhibitors
2,880 (3.7) 1,116 (38.7)
Diuretics 1,575 (2.0) 897 (56.9)
Beta blocking agents 1,387 (1.8) 552 (39.8)
Calcium channel blockers 799 (1.8) 217 (27.1)
Antiarrhythmics 494 (0.6) 233 (47.2)
Lipid modifying agents 340 (0.4) 126 (37.0)
Digitalis glycosides (digoxin) 333 (0.4) 238 (71.5)
(Continued)Frontiers in Pharmacology | www.frontiersin.org 5TABLE 2 | Continued
Drug class ED visits for
ADEs










300 (0.4) 77 (25.7)




Diabetes agents 6,042 (7.7) 3,215 (53.2)
Insulin 3,654 (4.7) 1,819 (49.8)
Oral diabetes agents 2,388 (3.0) 1,396 (58.4)
Anti-ulcer and antacid agents 743 (0.9) 182 (24.5)
Propulsives (metoclopramide) 307 (0.4) 83 (27.0)
Antidiarrheals 283 (0.4) 65 (23.0)
Drugs for constipation 158 (0.2) 44 (27.8)
Stomatological preparations 152 (0.2) 30 (19.7)
Other gastrointestinal agents 465 (0.7) 129 (27.7)
Musculoskeletal system 7,717 1,892
Nonsteroidal anti-inflammatory
drugs
6,617 (8.4) 1,616 (24.4)
Ketoprofen 1,876 (2.4) 418 (22.3)
Ibuprofen 1,607 (2.0) 333 (20.7)
Diclofenac 1,075 (1.4) 315 (29.3)
Nimesulide 570 (0.7) 162 (28.4)
Ketorolac 289 (0.4) 98 (33.9)
Naproxen 279 (0.4) 79 (27.6)
Etoricoxib 226 (0.3) 59 (26.1)
Others 695 (0.9) 152 (21.9)
Muscle relaxants
(thiocolchicoside)
422 (0.5) 91 (21.6)
Antigout preparations
(allopurinol)
300 (0.4) 122 (40.7)
Topical products 263 (0.3) 32 (12.2)




Antineoplastic agents 1,252 (1.6) 679 (54.2)
Immune modulators 370 (0.5) 124 (33.5)
Endocrine therapy 100 (0.1) 30 (30.0)
Respiratory system 1,459 282
Nasal, cough and cold
preparations
813 (1.0) 146 (17.9)
Bronchodilators 421 (0.5) 84 (19.9)
Antihistamines for systemic use 225 (0.3) 52 (23.1)
Hormonal preparations 1,146 326
Corticosteroids for systemic use 864 (1.1) 259 (30.0)
Thyroid therapy 250 (0.3) 54 (21.6)






467 (0.6) 92 (19.7)
Drugs used in benign prostatic
hypertrophy (tamsulosin)
378 (0.5) 85 (22.5)
Other gynaecological agents 125 (0.2) 14 (11.2)
Other agents 1,404 198
Total agents 78,361 (100) 26,335 (33.6)April 2020 | Volume 11 | Article 412
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Acetylsalicylic acid 1,523 (5.78)
Amoxicillin-clavulanate 898 (3.41)












Patients aged ≤19 y


























Patients aged ≥65 y





Acetylsalicylic acid 1,286 (8.38)





Metformina and sulfonylureas 258 (1.68)
Amoxicillin-clavulanate 246 (1.60)





Glimepiride 184 (1.20)Frontiers in Pharmacology | www.frontiersin.org 6TABLE 4 | Adverse event manifestation by most commonly reported suspected
drug classes.












Haemorrhage 10,719 (50.5) 4,286 (40.0)
Epistaxis 3,559 (16.76) 346 (9.7)
Gastrointestinal 3,083 (14.5) 2,058 (67.0)
Genitourinary 1,221 (5.7) 429 (35.1)
Central nervous system 1,142 (5.4) 924 (80.9)
Dermatologic 1,018 (4.8) 407 (40.0)
Pulmonary 365 (1.7) 103 (28.2)
Ophthalmic 331 (1.5) 19 (5.7)
Altered international normalized
ratio
1,966 (9.3) 524 (26.6)
Anaemia 994 (4.7) 880 (88.5)
Unintentional or intentional
overdose




Dermatologic reaction 9,710 (42.7) 1,546 (15.9)
Urticaria 3,208 (14.1) 441 (13.7)
Localized or general pruritus 2,674 (11.8) 442 (16.5)
Erythema 2,001 (8.8) 399 (19.9)
Rash 1,827 (8.0) 264 (14.4)
Localized or peripheral edema 1,484 (6.5) 324 (21.8)
Gastrointestinal disturbance 2,296 (10.1) 460 (20.0)
Nausea or vomiting 1,064 (4.7) 218 (20.5)
Abdominal pain 644 (2.8) 126 (19.6)
Diarrhoea 588 (2.6) 116 (19.7)
Unspecified hypersensitivity 1,050 (4.6) 203 (19.3)
Neurological effect 1,029 (4.5) 229 (22.2)
Respiratory reaction 844 (3.7) 233 (27.6)
Dyspnea 684 (3.0) 193 (28.2)
Throat tightness 160 (0.7) 40 (25.0)





Dermatologic reaction 3,391 (27.9) 521 (15.4)
Urticaria 1,348 (11.1) 188 (13.9)
Localized or general pruritus 961 (7.9) 156 (16.2)
Erythema 552 (4.5) 97 (17.6)
Rash 530 (4.3) 80 (15.1)
Gastrointestinal disturbance 1,757 (14.4) 643 (36.6)
Abdominal pain 813 (6.7) 228 (28.0)
Nausea or vomiting 500 (4.1) 147 (29.4)
Melena 181 (1.5) 136 (75.1)
Gastritis 140 (1.1) 38 (27.1)
Hematemesis 123 (1.0) 94 (76.4)
Localized or peripheral edema 1,366 (11.2) 263 (19.2)
Unspecified hypersensitivity 434 (3.6) 73 (16.8)
Respiratory reaction 324 (2.7) 93 (28.7)
Abuse or self-harm 157 (1.3) 97 (61.8)
Insulin + Oral diabetes agents
N = 6,042
6,723 3,697
Hypoglycaemia (from mild to
severe)
3,006 (44.7) 1,560 (51.9)
Hypoglycaemia-related symptoms 992 (14.7) 634 (63.9)
(Continued)April 2020 | Volume 11 | Article 412
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pharmacovigilance study, conducted with an “active” approach,
designed to estimate the risk of hospitalization associated with
ADE, for a long period of observation and in a representative
number of Italian EDs. For the first time, the characteristics of
the entire MEREAFaPS Study database (demographic and
clinical characteristics of patients, ATC classes, SOC, and PT)
have been described. Based on the evidence herein reported,Frontiers in Pharmacology | www.frontiersin.org 7Italian medical doctors should be aware of the population subset
and pharmacological treatments most frequently associated to
ADEs in our country, considering that the elderly, females,
exposure to more than two concomitant medications, and
being treated with anticoagulants, analgesics, sedative or
hypnotic agents and antibacterials are risk factors for ADE-
related hospitalizations.
In the last decades, several studies have been published on
ADEs as cause of ED visits and hospitalizations in European
countries. Baena et al. (2014) performed a cross-sectional study
in EDs of nine Spanish hospitals during a 3-month period. The
overall prevalence of negative clinical outcomes of medications
(NCOMs) was 35.7%. Authors estimated that about 81% of the
NCOMs could have been prevented. Authors’ evidence
confirmed their previous analysis in this field (Baena et al.,
2006). In their second study, weighted prevalence of lack of
safety, which could be compared with our incidence rate, was
2.4% (95% CI, 1.9–2.8). This difference is determined by another
approach to data collection. In fact, authors used a
questionnaire-based method to gather information about
patients’ medications and related health problems.
Nickel and colleagues (Nickel et al., 2013) identified the
frequency of drug-related problems (DRPs) among elderly
patients presenting to the ED of the University Hospital Basel,
Switzerland (May 2007-April 2009). Out of 633 patients, with a
median age of 81 years and amean Charlson comorbidity index of
2.5, 77 presented a DRP. 64 of them fulfilled the criteria “serious
condition”. Polypharmacy and certain medications, in particular
thiazides, antidepressants, benzodiazepines, anticonvulsants, were
the most frequently causes of DRPs. Focusing on the elderly
patients in our sample, we observed different pharmacological
classes than described by Nickel and colleagues. Particularly,
anticoagulants and antiplatelet agents, antidiabetic medications
(including insulin), and furosemide were the most frequently
reported. Notably, these medications are characterised by a high
prevalence of use in Italy (National Observatory on the Use of
Medicines (OsMed), 2019), but, differently from medications
reported by Nickel (i.e., thiazides, benzodiazepines, etc.), they
are generally not inappropriate in this subset.
Roulet et al. (2013) estimated the frequency and the severity
of drug-related visits in ED, in order to assess ADE recognition
by emergency physicians (October 2007-31 March 2008). In
their prospective cross-sectional single centre study in France, a
total of 95 out of 423 eligible patients experienced an ADE.
Emergency physicians correctly attributed 33 of these cases to a
medication-related problem. Authors concluded that ADEs are
frequent in EDs and are not always well recognised by emergency
physicians, especially when the drug is involved in a
multifactorial pathological condition. Comparing this
limitation to our methodology, since our monitors evaluated
all ED clinical charts with a positive anamnesis for the presence
of a pharmacological treatment, we could consider that the
involvement of trained monitors may allowed us to recognise
and collect the majority of ADE-related ED visits.
In Finland, Juntti-Patinen and colleagues (Juntti-Patinen
et al., 2006) determined the incidence of drug-related ED visitsTABLE 4 | Continued









Shock, loss of consciousness,
or seizures
514 (7.6) 347 (67.5)
Altered mental status 191 (2.8) 124 (64.9)
Presyncope or syncope 152 (2.3) 74 (48.7)
Acidosis 135 (2.0) 89 (65.9)
Neurological effect 708 (10.5) 403 (56.9)
Drowsiness 231 (3.4) 154 (66.7)
Hyperhidrosis 173 (2.6) 90 (52.0)
Muscular weakness 170 (2.5) 84 (49.4)
Aphasia, dizziness, or tremor 134 (2.0) 75 (56.0)
Therapeutic error 261 (3.9) 136 (52.1)
Gastrointestinal disturbance 192 (2.8) 95 (49.5)
Opioid + Non-opioid analgesics
N = 5,321
11,237 3,001
Neurological effect 2,549 (22.7) 568 (22.3)
Muscular weakness 615 (5.5) 111 (18.0)
Dizziness 558 (5.0) 81 (14.5)
Presyncope or syncope 355 (3.2) 92 (25.9)
Drowsiness 224 (2.0) 137 (61.2)
Hyperhidrosis 199 (1.8) 44 (22.1)
Altered mental status 199 (1.8) 77 (38.7)
Headache 139 (1.2) 26 (18.7)
Gastrointestinal disturbance 2,437 (21.7) 593 (24.3)
Nausea or vomiting 1,730 (15.4) 377 (21.8)
Abdominal pain 707 (6.3) 193 (27.3)
Constipation 78 (0.7) 26 (33.3)
Dermatologic reaction 1,587 (14.1) 229 (14.4)
Urticaria 592 (5.3) 72 (12.2)
Localized or general pruritus 479 (4.3) 75 (15.6)
Erythema 300 (2.7) 49 (16.3)
Rash 216 (1.9) 33 (15.3)
Localized or peripheral edema 287 (2.5) 60 (20.9)
Abuse or self-harm 190 (1.7) 111 (58.4)
Respiratory distress 189 (1.7) 52 (27.5)
Unspecified hypersensitivity 154 (1.4) 19 (12.3)
Sedative or hypnotic agents
N = 3,802
7,744 4,271
Neurological effect 2,553 (33.0) 1,607 (62.9)
Drowsiness 1,595 (20.6) 994 (62.3)
Altered mental status or
bradyphrenia
501 (6.5) 277 (55.3)
Loss of consciousness 158 (2.0) 110 (69.6)
Bradykinesia 157 (2.0) 112 (71.3)
Muscular weakness 142 (1.8) 48 (33.8)
Presyncope or syncope 130 (1.7) 66 (50.8)
Abuse or self-harm 1,962 (25.3) 1,273 (64.9)April 2020 | Volume 11 | Article 412
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involved over a period of 6 months. Of the 7,113 evaluated visits,
2.3% were “certainly” or “probably” drug-related, 1.4% were
related to adverse drug reactions (ADRs) and 0.9% to intentional
overdoses. The most common ADRs were gastrointestinal
symptoms caused by antibiotics, opioids, NSAIDs, or cytostatic
drugs. The ADR patients were older than the intentional
overdose patients. Males predominated in the intentional
overdose group but not in the ADR patients. Notably, in our
sample we observed different kind of ADEs, in particular
haemorrhages for anticoagulant and antiplatelet agents, and
dermatological reactions for both antibacterials for systemic
use and NSAIDs. These differences are probably driven by the
demographic and clinical characteristics of the Italian and
Finnish populations.
In Italy, Rosafio and colleagues (Rosafio et al., 2017)
retrospectively analysed data for children seeking medical
evaluation for a medication-related visits over an 8-year period
in a single tertiary centre. They found a total of 497 medication-
related visits, 54% of which occurred in children from 0 to 2 years
of age. The most common events were related to ADRs (30.3%).
The medication classes most frequently implicated in an ADE
were anti-infective drugs for systemic use, central nervous system
agents and respiratory system drugs. The most common
symptom manifestations were dermatologic conditions, general
disorder and administration site conditions and gastrointestinalFrontiers in Pharmacology | www.frontiersin.org 8symptoms. Another single-centre study performed in Italy on
children (Lombardi et al., 2018) confirmed the evidence reported
by Rosafio. In addition, young age and polypharmacy were found
to be predictive of ADR seriousness. Capuano et al. (2009)
described the characteristics of ADEs in 10 EDs of general
hospitals in southern Italy. Comparable to our evidence,
authors reported that ADEs were significantly more frequent
in women, in elderly, and in patients exposed to antibiotics,
NSAIDs, and agents acting on the renin-angiotensin system.
Also in this case, authors’ evidence confirmed their previous
results published in 2004 (Capuano et al., 2004). Trifirò and
colleagues (Trifiro et al., 2005), during the year 2000, performed
a prospective study in two observational periods of 10 days each
in 22 Italian EDs. On 18,854 enrolled patients, 629 (3.3%) were
affected by ADE. Among these, around 39% of ADE patients
reported a serious event. Patients with ADE were significantly
more likely to be hospitalized, females and elderly, compared
with the total sample. NSAIDs and antibiotics were the drugs
mostly involved in ADE occurrence, which affected mostly the
cutaneous and gastrointestinal systems. Although the above
mentioned evidence is comparable to that observed in our
study, particularly for gender, age groups, drug classes, ADE
types, seriousness and preventability, in Europe most of the
studies were performed in a single centre, with a short period of
observation, therefore considering a small sample of patients and
fewer adverse events. Actually, only an Italian evaluation hasFIGURE 1 | Predictors of hospitalization expressed as reporting odds ratio (ROR). CAM, complementary and alternative medicine.April 2020 | Volume 11 | Article 412
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initiative (Perrone et al., 2014). This article was the first
published in Italy, however it reported data from the EDs
enrolled in only one Region during a short observational
period. Actually, our data include those already presented by
Perrone et al., who described the impact of ADRs through a
retrospective 2-year analysis performed in 32 EDs of Lombardy
region (northern Italy). In their study authors collected a total of
8,862 ADRs with an overall prevalence rate of 3.5 per 1,000 visits.
Of all ADRs, 42% were probably/definitely preventable and
46.4% were serious, 15% required hospitalization, and 1.5%
resulted in death. The SOC most frequently associated with
ADRs were: skin and subcutaneous tissue, gastrointestinal,
respiratory thoracic and mediastinal, and nervous system
disorders. The most common ATC classes involved in ED
visits were anti-infectives and immunomodulating agents,
blood and blood-forming organs agents, and nervous system
agents. Older age and higher number of concomitantly taken
drugs were significantly associated with an increased risk of
hospitalization. Therefore, except for estimates regarding the
incidence rate per 1,000 visits (1.4 versus 3.5), evidence described
by Perrone is completely comparable to that we observed now at
Italian national level.
Comparing our evidence with that obtained from different
population setting, such as the American one, the most
frequently suspected drug classes implicated in ED visits and
hospitalizations for ADEs in Italy are the same identified by
Shehab and colleagues in the United States (Shehab et al., 2016).
In their study, anticoagulants, antibiotics, antidiabetics,
analgesics, and cardiovascular agents were implicated in the
majority ED visits and hospitalizations for ADEs, which
included clinically significant ADEs, such as haemorrhage
(anticoagulants), allergic reactions (antibiotics), hypoglycaemia
(diabetes agents), and moderate to severe neurological effect
(analgesics). Of notice, the differences observed for
medications belonging to the ATC class N, in particular for
opioid analgesics and sedative or hypnotic agents. In our sample,
ATC class N is the second most frequently reported therapeutic
group, while in the United States the nervous system agents
represent the fourth cause of ED visits and hospitalization
for ADE.
Interestingly, in Italy the frequency of ED visit and
hospitalization seems to be higher for sedative or hypnotic
agents once compared with other drug classes inducing both
acute or chronic toxicity (i.e., substance use disorder), such as
opioids. In fact, in our sample 53.3% of patients exposed to
sedative or hypnotic agents and admitted to the ED were
hospitalized, versus 25.6% of patients exposed to analgesics.
Similarly, differences in hospitalization frequency can be
observed for other medication groups. Further investigations
should be performed for direct thrombin inhibitors (48% of
hospitalizations), antidepressants (45%), antipsychotics (47%),
antiepileptics (47%), diuretics (57%), and oral diabetes
agents (58%).
The evidence provided in this article is comparable to the
majority of international publications (Zed et al., 2013), in termsFrontiers in Pharmacology | www.frontiersin.org 9of patients’ characteristics, drug classes and ADEs most
frequently reported. The highest percentage of female patients
with ADE observed in our EDs can simply reflect the
demographic data, since in Italy there are more female patients
(Italian Statistics Bureau (ISTAT), 2018), especially those over
the age of 65 years. Considering the characteristics of ADEs, they
are mainly common and related to the pharmacokinetics and
pharmacodynamics of the suspected drugs. Notably, our results
highlighted that patients exposed to two or more concomitant
suspected drugs were at statistically significant higher risk of
hospitalization compared to those exposed to only one suspected
drug. Therefore, our results may help identify which
pharmacological classes need a special attention from
professionals and healthcare systems in order to better
recognise ADEs in outpatients.
In summary, the elderly, females, patients exposed to more
than two concomitant medications, and those treated with
anticoagulants, analgesics, sedative or hypnotic agents and
antibacterials are at higher risk for a hospitalization related to
an ADE in Italy. Taking into account all these features could help
both general practitioners and ED physicians to prevent and
better manage ADEs. This update and an improvement of
appropriateness of prescription and use of medications, go
hand in hand to ameliorate drug safety.
Although an individual patient data meta-analysis highlighted
that risk factors associated with ADEs in hospitalized patients are
quite comparable with those observed in our sample for out-
patients, since we excluded these cases from our analysis, it could
be interesting to perform future investigations on this topic,
comparing them with evidence already published (Sakuma
et al., 2012; Boeker et al., 2015; Sakuma et al., 2020).
Strengths and Limitations
There are a number of study limitations. First, this study includes
only ADEs diagnosed and treated in EDs. Furthermore, the
evaluated setting, trained monitors’ expertise (i.e., clinical
pharmacology and clinical pharmacy), and the methods used
to identify ADEs can lead to a reporting bias that favoured the
detection of events, which are generally more common and
serious, therefore easier to detect (i.e., bleeding and
hypoglycaemia). Nevertheless, having considered all cases that
reported a pharmacological treatment in anamnesis may have
reduced the reporting bias. Second, the retrospective nature of
the study may have led to an underestimation of ADEs rate, since
not all patients presenting an ADE, even if serious, attend ED or
spontaneously report the ADE. However, considering that data
on ADE reports were collected through a national active
pharmacovigilance initiative, the issue of underreporting can
be considered of relatively low relevance. Third, our analysis is
based on ADE reports that are affected by limits that include
inaccurate and incomplete information, mainly related to lack of
clinical data also in the ED electronic sources (i.e., clinical chart
and hospital discharge database). Given that, the absence of
information that was not listed in ADE reports and that might
have influenced the clinical evaluation of each report (i.e., the
lack of information on previous and/or current patient medicalApril 2020 | Volume 11 | Article 412
Lombardi et al. Adverse Drug Events in Outpatientsconditions which could affect the clinical evaluation of each case)
could not always be excluded, particularly for the assessment of
preventability. Despite these limitations, this is the first
nationwide multicentre study performed in Italy on the ADEs
associated to ED visits and hospitalizations, over 12-year of
observation. Moreover, our study involved different catchment
areas of Italy (hospitals are equally distributed through the
national territory), thus the evidence herein reported can be
considered representative of all Italian EDs.CONCLUSION
Targeting ADEs common among specific patient populations,
such as the elderly (age ≥65 years), women and patients exposed
to two or more concomitant suspected drugs, may help further
focus on outpatients’ medication safety in order to early
recognise and prevent ADEs. In the frame of EDs, active
pharmacovigilance studies represent the best observational
methodology, allowing healthcare professionals and systems to
detect, collect and characterise the clinical burden of ADEs in
outpatients. The MEREAFaPS Study described here is the largest
conducted on ADE reports in Europe and can represent a reliable
data source to carry out real-world drug-safety studies.
Furthermore, to put our data and identified risk factors
associated with hospitalization due to ADEs into a future
perspective, it will be important to compare our sample with a
large group of ED patients without ADEs, hospitalized, and not
hospitalized. Further analysis is certainly need and will be carried
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